MicroVascular Tissues Reports Positive Results for HIFLO Trial Demonstrating Increased Closure and High Quality of Healing Using mVASC(R) Microvascular Tissue Graft

Data From 100-Patient Randomized, Controlled Trial on Nonhealing Diabetic Foot Ulcers Presented at SAWC Fall 2020 SAN DIEGO, Nov. 10, 2020 -- (Healthcare Sales & Marketing Network) -- MicroVascular Tissues, Inc., (MVT), a regenerative medicine company,... Regenerative Medicine, Wound Care MicroVascular Tissues, mVASC , Microvascular Tissue Graft, diabetic foot ulcers
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news